Key Highlights

  • Proteome Sciences plc LSE:PRM gained 14.29% on 15 September 2026, placing it among the strongest healthcare movers in the latest market snapshot.
  • The company has recently secured another significant target-engagement and chemoproteomics contract, reinforcing momentum in its services business.
  • Proteome Sciences reported £3.76 million Revenue for 2025, with proteomic services revenue more than doubling to £2.06 million.
  • The company has been investing heavily in its clinical proteomics capabilities, including target engagement, biomarker discovery and single-cell proteomics.
  • Two further substantial contracts announced in January 2026 added to the company's order momentum.
  • Investors are watching whether the rapid growth of the services division can offset weakness in TMT® reagent and Royalty revenue and move the company towards sustainable profitability.

Why Is Proteome Sciences LSE:PRM in Focus Today?

Proteome Sciences plc LSE:PRM has emerged as another notable UK healthcare mover on 15 September 2026, with its shares gaining 14.29%.

The company operates in the specialised field of proteomics, providing analytical services and technologies used in drug discovery, biomarker research and pharmaceutical development.

The latest share-price move comes against a backdrop of improving commercial momentum in its services operation. In June 2026, Proteome Sciences announced another significant contract related to its target-engagement and chemoproteomics platform, highlighting growing Demand from pharmaceutical and biotechnology customers.

The company is therefore attracting attention because investors are increasingly assessing whether its service-led strategy can create a more sustainable and scalable revenue base.

Could the Latest Chemoproteomics Contract Be Driving Investor Interest?

Proteome Sciences announced in June that it had secured a further significant clinical contract connected with its target-engagement and chemoproteomics platform.

Target engagement is important in drug discovery because researchers need to understand whether a potential therapeutic compound interacts with its intended biological target and how that interaction behaves inside cells.

Proteome Sciences' technology and expertise are designed to provide pharmaceutical and biotechnology companies with detailed molecular information that can help guide drug-development decisions.

The continued award of contracts in this area suggests that the company's specialist capabilities are gaining commercial traction.

While the exact value of the latest contract was not disclosed, the announcement reinforces a broader trend visible in Proteome Sciences' recent Business development: clinical and proteomic services are becoming increasingly important to the company's revenue mix.

Why Are Proteomic Services Becoming More Important?

Proteome Sciences' 2025 results provide an important indication of this transition.

Total revenue fell to £3.76 million from £4.89 million in 2024. However, the decline was primarily caused by lower TMT® reagent sales and royalties.

At the same time, proteomic services revenue more than doubled to £2.06 million from £0.87 million.

This is strategically important because it demonstrates that the company's services business is expanding even while its traditional reagent-related revenue stream has faced pressure.

Management described 2025 as potentially representing the bottom of the company's Business Cycle and highlighted expectations for future growth from its services operation alongside a potential recovery in TMT® reagent sales.

For investors, the key question is whether the services business can continue growing quickly enough to establish a stronger overall revenue trajectory.

What Is Driving Demand for Proteome Sciences’ Services?

Proteome Sciences operates at the intersection of biotechnology, pharmaceutical research and advanced analytical science.

Its services include areas such as target engagement, biomarker discovery, quantitative proteomics and single-cell proteomics.

These technologies can help pharmaceutical companies understand how drugs interact with biological systems, identify potential biomarkers and analyse molecular changes associated with disease.

The growth of precision medicine and increasingly complex drug-development programmes creates potential long-term demand for these capabilities.

Proteome Sciences has also been developing its single-cell proteomics capabilities. During 2025, the company completed a large customer project involving more than 5,000 cells, identifying over 3,300 proteins and achieving close to 900 quantifiable proteins across all cells.

This illustrates the technical depth of the company's platform and its ability to handle large-scale proteomic datasets.

Could TMT® Recovery Provide an Additional Catalyst?

Although services are becoming increasingly important, Proteome Sciences has not abandoned its established TMT® business.

TMT® reagents and associated royalties generated £1.70 million in 2025, down sharply from £4.01 million in 2024. (investegate.co.uk)

The decline was a significant Factor behind the group's overall revenue reduction.

Management expects the reagent business to recover as customers return to higher levels of research activity. If that recovery occurs while proteomic services continue expanding, Proteome Sciences could benefit from two separate growth drivers.

The company is also developing new reagent technologies. Its 2025 results highlighted a provisional Patent covering tri-functional linkers, with prototype synthesis completed and further development planned during 2026.

Why Are Investors Watching the Company's Contract Pipeline?

Contract wins are particularly important for a company of Proteome Sciences' size.

In January 2026, the company announced two further substantial contracts, following another substantial contract announced in December 2025. The January awards were connected to its growing services business and added visibility to future activity. (proteomics.com)

The June chemoproteomics contract provides further evidence that the company continues to attract pharmaceutical and biotechnology customers.

Investors will therefore be watching whether contract frequency and size continue to increase during the remainder of 2026.

A sustained improvement in contract wins could provide greater revenue visibility and potentially improve market confidence in the company's growth strategy.

What Are the Financial Challenges Facing LSE:PRM?

Despite the positive operational developments, Proteome Sciences remains financially challenged.

The company reported a £3.06 million loss after tax in 2025, although this represented an improvement from the £3.41 million loss reported in 2024.

Cash at the end of 2025 was approximately £0.78 million, compared with £1.13 million a year earlier. Adjusted EBITDA remained negative at approximately £1.72 million. (investegate.co.uk)

The company raised approximately £840,000 in January 2026, alongside a retail offer, providing additional resources for its operations and development programme.

Consequently, investors will remain focused on cash consumption, contract growth and the path towards profitability.

What Should Investors Watch After the 14.29% Gain?

The latest share-price move places several developments firmly on the radar:

  • Further target-engagement and chemoproteomics contracts.
  • Growth in proteomic services revenue.
  • Recovery in TMT® reagent sales and royalties.
  • Development of single-cell proteomics.
  • Commercialisation of new reagent technologies.
  • Pharmaceutical and biotechnology customer wins.
  • Cash utilisation and funding requirements.
  • Progress towards positive EBITDA.
  • Expansion of the clinical research pipeline.

The company's latest market valuation remains very small. London Stock Exchange data showed a Market Capitalisation of approximately £4.9 million before today's move, highlighting why individual contracts and changes in investor demand can have an outsized impact on LSE:PRM.

Could LSE:PRM Continue Its Recovery?

Proteome Sciences' 14.29% gain on 15 September 2026 comes as the company attempts to build a new growth trajectory around its specialist services capabilities.

The most encouraging part of the story is the rapid expansion of proteomic services revenue, while recent contract wins suggest continuing commercial demand for its expertise in target engagement and chemoproteomics.

However, the company still needs to address its underlying profitability and cash-generation challenges. The decline in TMT® revenue remains an important offset to the services growth story.

If the company can continue winning significant pharmaceutical contracts, expand high-value proteomic services and achieve a recovery in reagent revenue, the current rally could develop into a broader reassessment of LSE:PRM.

For now, contract momentum, clinical proteomics demand and the potential recovery of TMT® revenue are the main factors keeping Proteome Sciences firmly in focus.